Serum biomarkers for Alzheimer's disease: Proteomic discovery

Dwight C. German, Prem Gurnani, Animesh Nandi, Harold R. Garner, Wayne Fisher, Ramon Diaz-Arrastia, Padraig O'Suilleabhain, Kevin P. Rosenblatt

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

For Alzheimer's disease (AD), the most common neurodegenerative disease, there is no simple, cost-effective biomarker for disease identification. Using novel mass spectrometry (MS)-based techniques, and analysis of the albumin-enriched low molecular weight proteome, minute amounts of human serum were analyzed for the measurement of thousands of peptides and proteins in parallel. The mass spectrograms were then evaluated with a novel computer algorithm to identify spectral peaks that discriminate between samples from patients with and without AD. There are four peaks that distinguish AD from control subjects and AD subjects from those with Parkinson's disease (PD). Additionally, after analyzing data from a recently published study of AD and control subjects, we found three discriminating peaks in common with the four from our patient serum samples. The identification of these peptides/proteins, and their direct measurement in patient serum, may allow the development of a simple, cost-effective test for AD.

Original languageEnglish (US)
Pages (from-to)383-389
Number of pages7
JournalBiomedicine and Pharmacotherapy
Volume61
Issue number7
DOIs
StatePublished - Aug 2007

Fingerprint

Proteomics
Alzheimer Disease
Biomarkers
Serum
Costs and Cost Analysis
Peptides
Proteome
Neurodegenerative Diseases
Parkinson Disease
Albumins
Mass Spectrometry
Proteins
Molecular Weight

Keywords

  • Albumin-bound fraction
  • Biomarkers
  • MALDI O-TOF
  • Parkinson's disease

ASJC Scopus subject areas

  • Pharmacology

Cite this

German, D. C., Gurnani, P., Nandi, A., Garner, H. R., Fisher, W., Diaz-Arrastia, R., ... Rosenblatt, K. P. (2007). Serum biomarkers for Alzheimer's disease: Proteomic discovery. Biomedicine and Pharmacotherapy, 61(7), 383-389. https://doi.org/10.1016/j.biopha.2007.05.009

Serum biomarkers for Alzheimer's disease : Proteomic discovery. / German, Dwight C.; Gurnani, Prem; Nandi, Animesh; Garner, Harold R.; Fisher, Wayne; Diaz-Arrastia, Ramon; O'Suilleabhain, Padraig; Rosenblatt, Kevin P.

In: Biomedicine and Pharmacotherapy, Vol. 61, No. 7, 08.2007, p. 383-389.

Research output: Contribution to journalArticle

German, DC, Gurnani, P, Nandi, A, Garner, HR, Fisher, W, Diaz-Arrastia, R, O'Suilleabhain, P & Rosenblatt, KP 2007, 'Serum biomarkers for Alzheimer's disease: Proteomic discovery', Biomedicine and Pharmacotherapy, vol. 61, no. 7, pp. 383-389. https://doi.org/10.1016/j.biopha.2007.05.009
German, Dwight C. ; Gurnani, Prem ; Nandi, Animesh ; Garner, Harold R. ; Fisher, Wayne ; Diaz-Arrastia, Ramon ; O'Suilleabhain, Padraig ; Rosenblatt, Kevin P. / Serum biomarkers for Alzheimer's disease : Proteomic discovery. In: Biomedicine and Pharmacotherapy. 2007 ; Vol. 61, No. 7. pp. 383-389.
@article{098a66dd41ed455bad1b0752e4b9c907,
title = "Serum biomarkers for Alzheimer's disease: Proteomic discovery",
abstract = "For Alzheimer's disease (AD), the most common neurodegenerative disease, there is no simple, cost-effective biomarker for disease identification. Using novel mass spectrometry (MS)-based techniques, and analysis of the albumin-enriched low molecular weight proteome, minute amounts of human serum were analyzed for the measurement of thousands of peptides and proteins in parallel. The mass spectrograms were then evaluated with a novel computer algorithm to identify spectral peaks that discriminate between samples from patients with and without AD. There are four peaks that distinguish AD from control subjects and AD subjects from those with Parkinson's disease (PD). Additionally, after analyzing data from a recently published study of AD and control subjects, we found three discriminating peaks in common with the four from our patient serum samples. The identification of these peptides/proteins, and their direct measurement in patient serum, may allow the development of a simple, cost-effective test for AD.",
keywords = "Albumin-bound fraction, Biomarkers, MALDI O-TOF, Parkinson's disease",
author = "German, {Dwight C.} and Prem Gurnani and Animesh Nandi and Garner, {Harold R.} and Wayne Fisher and Ramon Diaz-Arrastia and Padraig O'Suilleabhain and Rosenblatt, {Kevin P.}",
year = "2007",
month = "8",
doi = "10.1016/j.biopha.2007.05.009",
language = "English (US)",
volume = "61",
pages = "383--389",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",
number = "7",

}

TY - JOUR

T1 - Serum biomarkers for Alzheimer's disease

T2 - Proteomic discovery

AU - German, Dwight C.

AU - Gurnani, Prem

AU - Nandi, Animesh

AU - Garner, Harold R.

AU - Fisher, Wayne

AU - Diaz-Arrastia, Ramon

AU - O'Suilleabhain, Padraig

AU - Rosenblatt, Kevin P.

PY - 2007/8

Y1 - 2007/8

N2 - For Alzheimer's disease (AD), the most common neurodegenerative disease, there is no simple, cost-effective biomarker for disease identification. Using novel mass spectrometry (MS)-based techniques, and analysis of the albumin-enriched low molecular weight proteome, minute amounts of human serum were analyzed for the measurement of thousands of peptides and proteins in parallel. The mass spectrograms were then evaluated with a novel computer algorithm to identify spectral peaks that discriminate between samples from patients with and without AD. There are four peaks that distinguish AD from control subjects and AD subjects from those with Parkinson's disease (PD). Additionally, after analyzing data from a recently published study of AD and control subjects, we found three discriminating peaks in common with the four from our patient serum samples. The identification of these peptides/proteins, and their direct measurement in patient serum, may allow the development of a simple, cost-effective test for AD.

AB - For Alzheimer's disease (AD), the most common neurodegenerative disease, there is no simple, cost-effective biomarker for disease identification. Using novel mass spectrometry (MS)-based techniques, and analysis of the albumin-enriched low molecular weight proteome, minute amounts of human serum were analyzed for the measurement of thousands of peptides and proteins in parallel. The mass spectrograms were then evaluated with a novel computer algorithm to identify spectral peaks that discriminate between samples from patients with and without AD. There are four peaks that distinguish AD from control subjects and AD subjects from those with Parkinson's disease (PD). Additionally, after analyzing data from a recently published study of AD and control subjects, we found three discriminating peaks in common with the four from our patient serum samples. The identification of these peptides/proteins, and their direct measurement in patient serum, may allow the development of a simple, cost-effective test for AD.

KW - Albumin-bound fraction

KW - Biomarkers

KW - MALDI O-TOF

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=34547813002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547813002&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2007.05.009

DO - 10.1016/j.biopha.2007.05.009

M3 - Article

C2 - 17614251

AN - SCOPUS:34547813002

VL - 61

SP - 383

EP - 389

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 7

ER -